SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Corcept Reports No New Safety Signals in BELLA Trial

Corcept Therapeutics said no new safety signals were identified in the BELLA trial for its Lifyorli combination.

CORT

Related stories